Electra Therapeutics
South San Francisco, California, United States · Biotechnology, Health Care, Manufacturing
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 36
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (ETRA)
- Website
- electra-therapeutics.com
- Company page
Recent activity at Electra Therapeutics
- : Electra Therapeutics Promotes Chris Clark to Chief Financial Officer
- : Electra receives $30M venture debt facility from J.P. Morgan to advance toward its first commercial facility.
- : Electra Therapeutics raises USD 183 million in Series C financing, co-led by EQT Life Sciences and Nextech, to fund Phase 2/3 clinical studies for its innovative immune-targeting treatments.
- : Electra secures $186M Series B funding round co-led by Capricorn Investment Group and Temasek (date Fundz recorded it)
- : Electrasteel
- : Electra and Interfer Sign MOU to Collaborate on Clean Iron and Green Steel Production (date Fundz recorded it)
- : Electra Therapeutics, Inc. announces FDA Fast Track designation for ELA026 to treat secondary hemophagocytic lymphohistiocytosis.
- : Electrasteel Inc. Appoints James Rutland as Chief Financial Officer and Steve MacManus as Vice President of Engineering
- : Electra Therapeutics Appoints Graham Parry as Chief Scientific Officer and Kim-Hien Dao as Chief Medical Officer
- : Electra appoints Kellyn Blossom as Head of Communications and Policy in Washington, D.C.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Electra Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Debt Financing | $30.0M |
| Oct 2025 | Series C | $183.0M |
| Dec 2024 | Venture | $180.4M |
| Feb 2022 | Series B | $84.0M |
Leadership
- Chris Clark, Chief Financial Officer
- Peter Rawlins, Chief Financial Officer
- James Rutland, Chief Financial Officer
- Sandeep Nijhawan, Founder
- Steve MacManus, Vice President of Engineering
- Kim-Hien Dao, Chief Medical Officer
- Graham Parry, Chief Scientific Officer
- Kellyn Blossom, Head of Communications
- Kathy Dong, Chief Executive Officer
Verified email and direct lines for Electra Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Companies similar to Electra Therapeutics
- The Hain Celestial Group · Biotechnology, Health Care, Manufacturing, Science And Engineering, Sustainability
- Advanced NanoTherapies · Biotechnology, Health Care, Manufacturing, Science And Engineering
- American Bitcoin · Biotechnology, Health Care, Mining, Science And Engineering
- Drug Development Solutions (An LGC Business Unit) · Biotechnology, Health Care, Manufacturing, Science And Engineering
- PRISYM ID · Biotechnology, Health Care, Manufacturing, Science And Engineering
About Electra Therapeutics: questions and answers
What does Electra Therapeutics do?
Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Where is Electra Therapeutics headquartered?
Electra Therapeutics is headquartered in South San Francisco, California, United States.
How many employees does Electra Therapeutics have?
Electra Therapeutics has about 36 employees.
Has Electra Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for Electra Therapeutics. The most recent, Debt Financing of $30.0M, was in Mar 2026.
Who leads Electra Therapeutics?
Sandeep Nijhawan is a Founder at Electra Therapeutics.
What is the latest news on Electra Therapeutics?
On Sep 9, 2026, Electra Therapeutics Promotes Chris Clark to Chief Financial Officer
Is Electra Therapeutics a public company?
Yes. Electra Therapeutics is publicly traded under the ticker ETRA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy